New hope for deadly lung fungus: cheaper pill may replace toxic IV
NCT ID NCT05468372
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tested two medicines for a severe lung infection called pulmonary mucormycosis, which has a high death rate. The standard treatment, amphotericin B, is given through an IV and can cause serious side effects. The study compared it to posaconazole, a pill that may be easier and safer. 82 adults with the infection took part to see if posaconazole works as well as the standard drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCORMYCOSIS; PULMONARY (ETIOLOGY) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Postgraduate Institute of Medical Education and Research
Chandigarh, Chandigarh, 160012, India
Conditions
Explore the condition pages connected to this study.